Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis

OBJECTIVE: To evaluate cost-utility of infliximab and adalimumab for the treatment of moderate-to-severe ulcerative colitis (UC) refractory to conventional therapies in Canada. METHODS: A Markov model was constructed to evaluate incremental cost-utility ratios (ICUR) of 5 mg/kg and 10 mg/kg inflixim...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Xie, Feng, Blackhouse, Gord, Assasi, Nazila, Gaebel, Kathryn, Robertson, Diana, Goeree, Ron
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2009
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2797497/
https://ncbi.nlm.nih.gov/pubmed/20003364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1478-7547-7-20
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items